20 results about "RNA Aptamers" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to a recombinant RNA aptamer as well as a preparation method and application thereof. The recombinant RNA aptamer is obtained by taking active tRNA as a bracket, embedding an RNA aptamer and expressing in escherichia coli. The sequence of the active tRNA is a sequence which is similar to a human cysteine tRNA sequence by 90% or more, and the human cysteine tRNA sequence is shown as SEQ ID NO. 1; the RNA aptamer is directly embedded at an active tRNA anticodon, and the embedded sequence is a sequence with the similarity of more than 50% with the SEQ ID NO.2 sequence. According to the production method of the recombinant RNA aptamer, various RNA aptamers can be conveniently and quickly prepared, and the produced and prepared recombinant RNA aptamer can be used for preparing a medicine for treating arthritis and meets the requirements of scientific research and medicine research and development.

The present invention relates to a probe set for an isothermal single reaction using a split T7 promoter and a use thereof. In the present invention, a design is made to introduce a split T7 promoter into a 3-way junction structure to produce a large quantity of fluorescent RNA aptamers at an isothermal temperature in the presence of a target molecule, and a nucleic acid biomarker can be detected rapidly and conveniently with only one enzyme in one pot. The probe set allows for various applications through high-sensitivity detection of multiple nucleic acid biomarkers and detection in which analysis is performed without an additional nucleic acid extraction process. In one pot, multiplex analysis can be conducted and molecular diagnosis can be made of various entities including viruses and pathogens.

Compositions and methods for aptamer-mediated delivery of therapeutic agents. RNA aptamers identified via SELEX specifically bind and are internalized by cardiomyocytes or cardiac fibroblasts, delivering antisense oligonucleotides or other therapeutics intracellularly. This strategy offers a non-viral, targeted approach for treating cardiac diseases and may be extended to other tissues or therapeutic modalities.

An object of the present invention is to provide RNA aptamers capable of binding to ASP7967 or analogs thereof. The RNA aptamer of the present invention is an RNA aptamer that binds to ASP7967 or an analog thereof, and has the sequence: -X1-L1-X2-L2-X3- (wherein X1 has the sequence Y1GY2GY3Y4Y5; L1 is a first stem-loop nucleotide sequence comprising a first stem region, a first loop region, and a second stem region, wherein the first stem region and the second stem region are two or more base pairs in length and are substantially complementary to each other; X2 is A, G, C, or U; L2 is a second stem-loop nucleotide sequence comprising a third stem region, a second loop region, and a fourth stem region, wherein the third stem region and the fourth stem region are two or more base pairs in length and are substantially complementary to each other; the first base in the third stem region is G and the last base in the fourth stem region is C; and X3 has the sequence UY6). , Y1, Y2, Y3, Y4, Y5, and Y6 are each independently A, G, C, or U), or a third stem loop region comprising the sequence: -S1-X2-L2-X3-L3-X1-S2- (wherein S1 and S2 are each independently A, G, C, or U, and S1 and S2 can form base pairs or wobble base pairs with each other, and L3 comprises a fifth stem region, a third loop region, and a sixth stem region). the fifth stem region and the sixth stem region are one or more base pairs in length and are substantially complementary to each other, and X1, X2, X3, and L2 are as defined above), or the sequence: -S3-X3-L3-X1-L1-X2-S4- (wherein S3 is C, S4 is G, and X1, X2, X3, L1, and L3 are as defined above).

The present invention relates to an in vivo method for comparing the specific plasmid titers in two or more bacterial cell populations, using RNA aptamers.

The invention provides a method for screening a targeted binding RNA molecule by using a fluorescent RNA aptamer, and particularly, the method comprises the following steps: fusing the fluorescent RNA aptamer and a target RNA to obtain a fused RNA, co-incubating the fused RNA, a fluorescent agent and a molecule to be detected, then carrying out fluorescence measurement, and screening the molecule targeting the target RNA according to fluorescence change.

The invention concerns single-stranded RNA aptamers and uses thereof. Pharmaceutical compositions comprising such aptamers and uses thereof in the medical field, particularly in the treatment of neurodegenerative diseases, are also described.

Compositions and methods for amplifying RNA by replication using transcription polymerases are disclosed. Such replicated RNAs can be used in various applications such as RNAi therapeutics, diagnostic probes, RNA sequencing, directed evolution of RNA aptamers without intermediate conversion to DNA, and RNA vaccines. The transcription polymerases comprise T7 bacteriophage RNA polymerase.

The present invention relates to a method for detecting a target nucleic acid in a sample using an optimized SMART method that involves the use of at least one fluorescence-generating aptamer for the direct detection of RNA transcripts. Preferably, the method is used after an amplification step, for example, after a NASBA assay.

Disclosed herein are dual-specificity (DS) aptamers involving modular designed RNA that connect two aptamer motifs with a linker domain. In cells, they induce proximity between O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) and a designated protein, and increase or decrease O-GlcNAcylation on the substrate. These RNA aptamers have short half-lives in cells and their binding can be controlled by riboswitches.

Described herein and RNA aptamers that specifically bind to tumor-infiltrating myeloid cells and uses thereof.

This invention relates to a nanoparticle, its preparation method and application, and a drug comprising the nanoparticle for treating eye diseases and its preparation method. The nanoparticle comprises ribonucleic acid (RNA) and thiols, wherein the RNA comprises double-stranded RNA and RNA aptamers.

Provided herein are single guide RNAs (sgRNAs) that comprise aptamer sequences and related compositions and methods. Also provided herein are methods of selecting inducible sgRNAs that comprise aptamer sequences.

The invention relates to single-stranded DNA or RNA aptamers and uses thereof. Pharmaceutical compositions and kits comprising such aptamers and uses thereof in the medical field, in particular in the treatment of cancer, are also described.

A method of cyclizing an L-RNA aptamer by modifying the aptamer with a 3′ azide and a 5′ alkyne group and using click chemistry reaction-based method. The cyclized L-RNA aptamers have improved binding properties and favour more in vitro / cell applications. Also disclosed is an L-oligonucleotide aptamer having linked ends.

The present disclosure is directed to RNA-regulated fusion proteins comprising a protein of interest and an RNA-regulated destabilization domain. Also disclosed are RNA aptamers that bind specifically to a RNA-regulated destabilization domain. Nucleic acid molecules encoding the RNA-regulated fusion proteins and RNA aptamers and methods of use thereof are also disclosed.

The invention relates to a fluorescent RNA (Ribonucleic Acid) functionalized hydrogel kit, a preparation method and a method for detecting colorectal cancer miRNA-126, solves the technical problem of how to detect miRNA-126 in blood or tissue samples and is suitable for portable detection, and fluorescent RNA functionalized hydrogel is prepared from methacrylic acid hyaluronic acid, an acryloyl-modified fluorescent RNA aptamer and N, N-dimethylformamide. The fluorescent RNA aptamer is obtained by crosslinking the fluorescent RNA aptamer and N, N '-methylene bisacrylamide, and the covalent crosslinking between the fluorescent RNA aptamer and the hydrogel can prevent the RNA aptamer from being released into the external environment, so that the stability and the anti-interference capability of the hydrogel kit are improved.

Disclosed herein is a method of identifying an L-RNA aptamer specific for a target nucleic acid. According to some embodiments of the present disclosure, the method comprises, in vitro transcribing the DNAs of the DNA library into D-RNAs, followed by identifying target-specific D-RNAs via negative and positive selections, and then producing the L-RNA aptamer based on the identified D-RNA. Also disclosed herein are two aptamers identified by the present method. According to some embodiments of the present disclosure, the two aptamers respectively comprise the nucleotide sequences of SEQ ID NOs: 1 and 2.

Provided, as a technique for increasing the sensitivity of a digital assay with a simpler operation, is a digital assay method for determining the concentration of a target DNA in a sample. The method comprises: (1) a procedure for providing a substrate having a chamber array region in which 10 thousand to 10 billion chambers in a volume of 1 attoliter to 50 nanoliters are arranged; (2) a procedure for introducing a solution containing a target DNA and a reaction reagent into the chamber and sealing the chamber in a liquid-tight manner to form a reactor; (3) a procedure for simultaneously carrying out, in the reactor, an isothermal amplification reaction for the target DNA and an RNA transcription reaction including RNA aptamers; (4) a procedure for detecting fluorescence emitted from a complex of a dye and the RNA aptamer in the reactor; and (5) a procedure for determining the concentration of the target DNA in the solution on the basis of the number of reactors in which the fluorescence has been detected. The concentration of the nucleoside triphosphate in the solution is 0.2-2.0 mM.

Provided herein are Anorogenic nucleosides (e.g., Anorogenic nucleoside triphosphates (NTPs), e.g., Anorogenic reversible terminator nucleoside triphosphates) which can be used in the synthesis of Anorogenic oligonucleotides (e.g., Anorogenic DNA or RNA oligonucleotides, such as Anorogenic RNA aptamers). The Anorogenic oligonucleotides (e.g., Anorogenic DNA or RNA oligonucleotides, such as, Anorogenic RNA aptamers) can be used as Anorogenic probes to detect targets (e.g., antigens, biomarkers).